Abiopharma

New Form EFFECT - Protalix BioTherapeutics, Inc. Filed: 2025-08-22 AccNo: 9999999995-25-002712 Size: 1 KB

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

General Announcement: Monthly update pursuant to Catalist Rule 704(22)

General Announcement: Thomson Medical Group Launches Johor Bay Mega Project of Over MYR18 Billion GDV

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

Mandatory Cash Dividend/ Distribution:

Cash Dividend/ Distribution :: Mandatory

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Withdraw - Cash Dividend/ Distribution :: Mandatory

Withdraw - Cash Dividend/ Distribution :: Mandatory

Withdraw - Cash Dividend/ Distribution :: Mandatory

Withdraw - Notice Of Record Date

Mandatory Cash Dividend/ Distribution:

Withdraw - Cash Dividend/ Distribution :: Mandatory